Business Wire

SHINE Creates Therapeutics Division, Will Attend 2019 European Association of Nuclear Medicine Conference

Share

SHINE Medical Technologies, LLC today announced the creation of a new division of the company — SHINE Therapeutics. The establishment of the division enhances the company’s ability to focus on filling critical future needs in the rapidly growing therapeutic isotope market, while continuing to leverage its radioisotope production expertise.

The company’s Therapeutics division will initially focus on the development and commercialization of lutetium‑177, or Lu‑177, a therapeutic isotope that is combined with a disease-specific targeting molecule to treat cancer. Targeting molecules deliver Lu‑177 atoms to cancer sites throughout the body, where they directly irradiate cancer cells.

The first Lu‑177-based targeted radiotherapy (for neuroendocrine tumors) reached the market in 2018. Many high-potential targeted molecules for the treatment of a range of other cancers with Lu-177 are currently under investigation. SHINE is also evaluating additional medical isotopes with therapeutic properties for future development.

Katrina Pitas, a 10-year veteran of SHINE who served most recently as the company’s vice president of business development, has been appointed vice president and general manager of SHINE Therapeutics.

“Targeted radiotherapy has the potential to fundamentally change the way cancer patients are treated,” Ms. Pitas said. “But a robust, reliable supply of therapeutic isotopes will be crucial as both the discipline and associated market continue to grow. Our Lu‑177 development program is well underway, and we look forward to bringing high-purity Lu‑177 to market.”

In May, the company entered an agreement with the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB Prague) that provides SHINE with a global, exclusive license to a novel separation technology that it will use to separate lutetium from enriched ytterbium targets. The technology will enable SHINE to produce non-carrier-added, high-specific-activity Lu‑177.

“We are excited to bring our core competencies and technology to serve the rapidly emerging therapeutic market,” said Greg Piefer, SHINE’s founder and CEO. “This market is particularly exciting, as it offers very promising therapies for patients who before now had difficult or impossible to treat late stage cancers. The focus of our new division is to ensure cancer patients have a reliable supply chain of isotopes as new drugs are approved.”

SHINE is continuing its efforts to bring molybdenum-99, or Mo‑99, to a global market experiencing shortages that directly affect patient care. Construction of the company’s first-of-its-kind isotope production facility in Janesville, Wis., where it will produce Mo‑99 using the company’s patented technology, is underway and progressing well.

European Association of Nuclear Medicine Annual Congress

SHINE will be exhibiting at the European Association of Nuclear Medicine (EANM) Annual Congress in Barcelona, Spain. The exhibit hall will be open Oct. 13-15. You can find SHINE at booth no. 23 near the center entrance to the exhibit hall.

About SHINE Medical Technologies LLC

Founded in 2010, SHINE is a development-stage company working to become a manufacturer of radioisotopes for nuclear medicine. The SHINE system uses a patented, proprietary manufacturing process that offers major advantages over existing and proposed production technologies. It does not require a nuclear reactor, uses less electricity, generates less waste and is compatible with the nation’s existing supply chain for Mo-99. In 2014, SHINE announced the execution of Mo-99 supply agreements with GE Healthcare and Lantheus Medical Imaging. In 2015, with the help of Argonne National Laboratory, GE Healthcare demonstrated that SHINE Mo-99 can act as a drop-in replacement for reactor-based Mo-99. In 2016, SHINE received regulatory approval from the Nuclear Regulatory Commission to construct its production facility. The company began construction of the facility in the spring of 2019. Learn more at https://shinemed.com.

Contact information

Rod Hise
Director, Marketing & Corporate Communications
pr@shinemed.com
608-530-5659

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Alibaba Cloud Powered $1B of GMV in 68 Seconds, with Zero Downtime During 11.1120.11.2019 02:00:00 CETPress release

Alibaba Cloud today detailed the core technologies used during the record-breaking, 24-hour global shopping festival. The data intelligence backbone of Alibaba Group applied multiple mature innovations to power the cloud infrastructure and other key AI-enabled features, enabling millions of businesses to reach hundreds of millions of consumers worldwide. Powerful cloud infrastructure supports extreme scalability and robustness Launched during the Apsara Conference in September, the third generation of X-Dragon architecture fully supported the shopping event. The Elastic Bare Metal Servers improved cost efficiency by 20%. X-Dragon servers seamlessly integrate computing platforms, including the Elastic Compute Service (ECS) bare metal server and virtual machines, in a single architecture. Tapping this strong foundation, Alibaba Cloud handled extreme scalability, processing USD1 billion of GMV (Gross Merchandise Volume) in the first 68 seconds of the event; volume hit USD10 billion of GMV

Schlumberger Announces Redemption of 100% of Outstanding 4.200% Senior Notes Due 2021 of Schlumberger Norge AS19.11.2019 21:41:00 CETPress release

Schlumberger Limited (“Schlumberger”) today announced that Schlumberger Norge AS, an indirect wholly-owned subsidiary of Schlumberger (“SLB Norge”), will redeem the entire outstanding principal amount of its 4.200% Senior Notes due 2021 (CUSIP Nos. 80685PAA6/R7562MAB3; ISIN Nos. US80685PAA66/USR7562MAB39 and Common Codes 56301178/56301313) (the “Notes”). The redemption date for the Notes is December 19, 2019 (the “Redemption Date”). The Notes are currently listed on the Official List of the Luxembourg Stock Exchange and admitted to trading on the Euro MTF market. The aggregate principal amount of the Notes outstanding is $500,000,000. The Notes will be redeemed on the Redemption Date at a redemption price for the Notes equal to (a) 100% of the aggregate principal amount being redeemed, plus (b) accrued and unpaid on the Notes from the last interest payment date to, but excluding, the Redemption Date, plus (c) a make-whole premium to be calculated three business days prior to the Redemp

Janssen Receives EU Marketing Authorisation for Darzalex®▼(daratumumab) in Combination with Lenalidomide and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible19.11.2019 19:14:00 CETPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) has granted marketing authorisation for Darzalex®(daratumumab) in combination with lenalidomide and dexamethasone (DRd) for the treatment of newly diagnosed multiple myeloma patients who are ineligible for autologous stem cell transplant (ASCT). The approval was based on results from the Phase 3 MAIA (MMY3008) study, published in The New England Journal of Medicine 3 earlier this year and presented at the American Society of Hematology (ASH) Annual Meeting in 2018. “Despite recent therapeutic advances, relapse of multiple myeloma is considered to be almost inevitable, becoming more challenging to treat following each relapse. This makes it even more important that we maximise our best response upfront to extend the first remission,” said Professor Thierry Facon, M.D., Service des Maladies du Sang, Hôspital Claude Huriez, Lille, France, and principal investigator of the MAIA study

Beacon Platform Deployed by Shell New Energies to Develop Innovative Solutions19.11.2019 18:47:00 CETPress release

Beacon Platform, Inc. announced today that Shell New Energies (“Shell”) has deployed Beacon to develop full-stack web applications using Beacon’s cloud-based developer platform and proprietary dependency graph technology. Beacon will empower Shell’s developers and data scientists to expedite development, testing, and deployment of innovative web-based applications to production for business users and customers, securely and at scale. The advanced capabilities within the Beacon Platform will help Shell quickly build and deploy innovative energy solutions. Beacon Platform is designed to make it easy for developers to write, share, and release code, access the data they need, build web-based applications, and run the analytics that power the business. The open architecture and transparent source code approach enables experimentation and collaboration on a scale that is not possible in a traditional black-box solution. Unlike black-box solutions, Beacon has a transparent source code model,

Sintavia Launches Green Trade Group for Additive Manufacturers19.11.2019 18:35:00 CETPress release

Sintavia, LLC, a leading additive manufacturer focused on the aerospace & defense industry, announced today at Formnext that it was co-founding a trade group for additive manufacturers focused on promoting the environmental benefits of AM over traditional methods of manufacturing. The new group, to be called the Additive Manufacturer Green Trade Association, or AMGTA, would be a non-commercial, unaffiliated organization open to any additive manufacturer that meets certain criteria relating to sustainability of production. “Very often in additive manufacturing we focus on the cost and time benefits of the technology, and do not equally consider the very real environmental benefits of AM over traditional manufacturing,” said Brian Neff, Sintavia’s Chief Executive Officer. “These benefits include improved end use design utility and improved industrial ecology of the fabrication process itself. The AMGTA’s purpose will be to raise awareness of these benefits within end market segments, in

Rockwell Automation Joins Forces with Accenture, Microsoft, PTC, ANSYS, and EPLAN to Help Businesses Simplify Digital Transformation19.11.2019 18:00:00 CETPress release

Businesses that are digitally transforming their operations need an ecosystem of partners that can help them simplify technology deployments and quickly achieve goals like higher productivity. The new Rockwell Automation Digital Partner Program connects companies to expertise and solutions from market leaders like Accenture, Microsoft, PTC, ANSYS, and EPLAN to streamline the implementation and enhance the quality of digital initiatives. Through the Digital Partner Program, businesses can consult with industry advisors to create roadmaps for their digital initiatives and learn how industrial IoT concepts like digital twin, the factory of the future and a connected workforce can improve their uptime and efficiency. During implementation, businesses will have access to integrated hardware, software and turnkey systems from industry leaders that improve business performance leveraging their existing assets. “Seamlessly connecting all levels of a business and turning raw data into powerful